Type 2 Diabetes

Metabolic·MeSH: Diabetes Mellitus, Type 2

Prevalence

10700.0 / 100K

Incidence

600.0 / 100K/yr

93 drugs in development·42 companies·63 clinical trials

Drug Pipeline by Phase

Approved(15)

Drug	Company
exenatide synthetic	Amneal Pharmaceuticals, Inc. (AMRX)
inpefa	LEXICON PHARMACEUTICALS, INC. (LXRX)
Janumet	Merck & Co., Inc. (MRK)
Januvia	Merck & Co., Inc. (MRK)
Jardiance	ELI LILLY & Co (LLY)
Jardiance®	ELI LILLY & Co (LLY)
linagliptin	Mylan II B.V. (MYL)
losartan	Teva Pharmaceutical Industries Limited (TEVA)
metformin	Inventiva S.A. (IVA)
Mounjaro	ELI LILLY & Co (LLY)
Mounjaro®	ELI LILLY & Co (LLY)
ozempic	Novo Nordisk A/S (NVO)
saxagliptin	Mylan II B.V. (MYL)
Trulicity	ELI LILLY & Co (LLY)
Trulicity®	ELI LILLY & Co (LLY)

Phase 3(24)

Drug	Company
AZD6793	ASTRAZENECA PLC (AZN)
BYDUREON	ENANTA PHARMACEUTICALS INC (ENTA)
cagrilintide	Novo Nordisk A/S (NVO)
Dulaglutide	ELI LILLY & Co (LLY)
Dulaglutide	ENANTA PHARMACEUTICALS INC (ENTA)
HDM1005 1	Crinetics Pharmaceuticals, Inc. (CRNX)
HDM1005 1	ENANTA PHARMACEUTICALS INC (ENTA)
HDM1005 2	ENANTA PHARMACEUTICALS INC (ENTA)
HDM1005 2	Crinetics Pharmaceuticals, Inc. (CRNX)
IBI362	Crinetics Pharmaceuticals, Inc. (CRNX)
icosema	Novo Nordisk A/S (NVO)
idegasp	Sanofi (SNY)
insulin glargine	Novo Nordisk A/S (NVO)
insulin glargine	ELI LILLY & Co (LLY)
insulin glargine/lixisenatide	Sanofi (SNY)
Mazdutide	ENANTA PHARMACEUTICALS INC (ENTA)
oral semaglutide	EMISPHERE TECHNOLOGIES INC (EMIS)
oral Semaglutide/Rybelsus	ENANTA PHARMACEUTICALS INC (ENTA)
ormd-0801	ORAMED PHARMACEUTICALS INC. (ORMP)
Retatrutide	ELI LILLY & Co (LLY)
Semaglutide	ENANTA PHARMACEUTICALS INC (ENTA)
semaglutide b	Novo Nordisk A/S (NVO)
semaglutide j	Novo Nordisk A/S (NVO)
sglt2 inhibitor	Sanofi (SNY)

Phase 2(15)

Drug	Company
ALN-4324	ALNYLAM PHARMACEUTICALS, INC. (ALNY)
asc30	CHINA PHARMA HOLDINGS, INC. (CPHI)
bti-320	NANOMIX CORP (BTHI)
bti-410	NANOMIX CORP (BTHI)
da-1241	MetaVia Inc. (MTVA)
GKT137831	Calliditas Therapeutics AB (CALT)
GSBR-1290	Structure Therapeutics Inc. (GPCR)
icovamenib	Biomea Fusion, Inc. (BMEA)
imb-1018972	MADRIGAL PHARMACEUTICALS, INC. (MDGL)
kds2010	SCILEX HOLDING CO (SCLX)
LY3457263	ELI LILLY & Co (LLY)
nnc0487-0111 subcutanous	Novo Nordisk A/S (NVO)
renal autologous cell therapy	PROKIDNEY CORP. (PROK)
vanoglipel	MetaVia Inc. (MTVA)
VK0612	Viking Therapeutics, Inc. (VKTX)

Phase 1(13)

Drug	Company
AGTX-2004 (DBPR211)	Agentix Corp. (AGTX)
Arginine hydrochloride	Cidara Therapeutics, Inc. (CDTX)
BP1001-A	BIO-PATH HOLDINGS, INC. (BPTH)
LY3209590	ELI LILLY & Co (LLY)
LY3549492	ELI LILLY & Co (LLY)
nnc0487-0111	Novo Nordisk A/S (NVO)
Orforglipron	ELI LILLY & Co (LLY)
PATAS Trifluoroacetate	Valneva SE (VALN)
pyroglutamate rongliflozin	SUNSHINE BIOPHARMA INC. (SBFM)
RO7204239	Crinetics Pharmaceuticals, Inc. (CRNX)
semaglutide l	Novo Nordisk A/S (NVO)
semaglutide m	Novo Nordisk A/S (NVO)
semaglutide n	Novo Nordisk A/S (NVO)

Preclinical(10)

Drug	Company
bt-200	BIORA THERAPEUTICS, INC. (BIOR)
dbsn device	Vyome Holdings, Inc (HIND)
diabetes therapy	PharmaCyte Biotech, Inc. (PMCB)
gpx-002	Genprex, Inc. (GNPX)
hydrogel candidates for type 2 diabetes	GELESIS HOLDINGS, INC. (GLS)
igc-1a	IGC Pharma, Inc. (IGC)
kl-2118	Luckwel Pharmaceuticals Inc. (LKYM)
modd1	Modular Medical Inc. (MODD)
pivot	Modular Medical Inc. (MODD)
small molecule fyn kinase inhibitor	NEXUS BIOPHARMA INC (NEXS)

Unknown(2)

Drug	Company
Sitagliptin	ENANTA PHARMACEUTICALS INC (ENTA)
type2 defense	Glucose Health, Inc. (GLUC)

Early Phase 1(1)

Drug	Company
GLP-1	ENANTA PHARMACEUTICALS INC (ENTA)

Phase 1/Phase 2(1)

Drug	Company
ALN-KHK	ALNYLAM PHARMACEUTICALS, INC. (ALNY)

Phase 4(12)

Drug	Company
Dapagliflozin 10mg Tab	ASTRAZENECA PLC (AZN)
gla-100	Sanofi (SNY)
gla-100	Sanofi (SNYNF)
iglarlixi	Sanofi (SNY)
iglarlixi	Sanofi (SNY)
insulin degludec	Sanofi (SNY)
insulin glargine	Sanofi (SNY)
Mazdutide	Crinetics Pharmaceuticals, Inc. (CRNX)
oral semaglutide	Novo Nordisk A/S (NVO)
Semaglutide	UNITED THERAPEUTICS Corp (UTHR)
Semaglutide	Crinetics Pharmaceuticals, Inc. (CRNX)
Tirzepatide	ELI LILLY & Co (LLY)

BioSniper tracks 93 drugs in development for Type 2 Diabetes across 42 companies.

There are 63 clinical trials targeting Type 2 Diabetes tracked by BioSniper.

The estimated prevalence of Type 2 Diabetes is approximately 10700.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.